GlassScriptPhysician profile
John Thomas Hess
NPI 1861846115
$2,061.58
in general payments reported to CMS, 2019-2025
27 companies · $523 in 2025
The $523 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $16.09 · 2022: $341 · 2023: $549 · 2024: $633 · 2025: $523.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,705.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,704.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $294.24 | 2023-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $284.50 | 2022-2025 | Rexulti, Nuedexta |
| Abbvie INC. | $198.66 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $171.01 | 2022-2024 | Austedo Xr, Austedo |
| Amgen INC. | $158.65 | 2022-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $153.33 | 2023-2025 | Trelegy Ellipta, Shingrix |
| Pfizer INC. | $83.10 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $75.19 | 2023-2025 | Airsupra, Farxiga |
| Exact Sciences Corporation | $74.98 | 2024 | Cologuard Collection Kit |
| Lilly USA, LLC | $71.62 | 2022-2024 | Mounjaro |
| Novo Nordisk INC | $67.23 | 2024 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $53.97 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $44.06 | 2022-2024 | |
| Paratek Pharmaceuticals, INC. | $36.26 | 2023-2024 | Nuzyra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.42 | 2024 | Xifaxan |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $32.16 | 2023 | |
| Sumitomo Pharma America, INC. | $29.86 | 2024 | Gemtesa |
| Abiomed | $27.70 | 2023 | Impella |
| Indivior INC. | $26.62 | 2023 | Perseris |
| Boston Scientific Corporation | $24.97 | 2025 | Watchman Flx |
| Regeneron Healthcare Solutions, INC. | $21.03 | 2023 | Evkeeza |
| Xeris Pharmaceuticals, INC. | $18.31 | 2022 | |
| Phathom Pharmaceuticals, INC. | $18.23 | 2024 | Voquezna |
| Avanir Pharmaceuticals, INC. | $16.09 | 2021 | |
| Abbott Laboratories | $15.56 | 2025 | Freestyle Libre 3 |
| Shield Therapeutics INC | $15.23 | 2025 | |
| Janssen Pharmaceuticals, INC | $13.60 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Hess listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.